Dynavax Technologies Toekomstige groei

Future criteriumcontroles 4/6

De verwachting is dat Dynavax Technologies de winst en omzet met respectievelijk 38.7% en 17.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 36.3% per jaar.

Belangrijke informatie

38.7%

Groei van de winst

36.3%

Groei van de winst per aandeel

Biotechs winstgroei	27.3%
Inkomstengroei	17.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	23 Oct 2024

Recente toekomstige groei-updates

Recent updates

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Winst- en omzetgroeiprognoses

NasdaqGS:DVAX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	377	65	69	96	3
12/31/2025	338	55	40	72	4
12/31/2024	281	25	2	18	5
6/30/2024	250	17	35	39	N/A
3/31/2024	236	9	53	56	N/A
12/31/2023	232	-6	96	101	N/A
9/30/2023	361	61	118	122	N/A
6/30/2023	459	111	147	152	N/A
3/31/2023	656	236	134	141	N/A
12/31/2022	723	293	56	63	N/A
9/30/2022	733	320	140	148	N/A
6/30/2022	674	228	142	153	N/A
3/31/2022	470	104	238	247	N/A
12/31/2021	439	72	326	336	N/A
9/30/2021	258	-39	192	199	N/A
6/30/2021	163	-6	101	105	N/A
3/31/2021	113	-62	-31	-27	N/A
12/31/2020	40	-75	-103	-92	N/A
9/30/2020	38	-97	-112	-100	N/A
6/30/2020	35	-138	-115	-94	N/A
3/31/2020	40	-129	-136	-108	N/A
12/31/2019	35	-156	-151	-121	N/A
9/30/2019	30	-159	-161	-132	N/A
6/30/2019	21	-163	-166	-144	N/A
3/31/2019	14	-160	-157	-141	N/A
12/31/2018	8	-159	-146	-131	N/A
9/30/2018	3	-146	-130	-115	N/A
6/30/2018	1	-128	-110	-99	N/A
3/31/2018	0	-109	N/A	-82	N/A
12/31/2017	0	-95	N/A	-78	N/A
9/30/2017	8	-89	N/A	-86	N/A
6/30/2017	8	-102	N/A	-97	N/A
3/31/2017	10	-111	N/A	-105	N/A
12/31/2016	11	-112	N/A	-107	N/A
9/30/2016	4	-118	N/A	-103	N/A
6/30/2016	5	-113	N/A	-97	N/A
3/31/2016	4	-108	N/A	-96	N/A
12/31/2015	4	-107	N/A	-93	N/A
9/30/2015	6	-102	N/A	-88	N/A
6/30/2015	7	-102	N/A	-88	N/A
3/31/2015	8	-103	N/A	-87	N/A
12/31/2014	11	-91	N/A	-74	N/A
9/30/2014	12	-90	N/A	-69	N/A
6/30/2014	12	-76	N/A	-58	N/A
3/31/2014	13	-68	N/A	-51	N/A
12/31/2013	11	-75	N/A	-59	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DVAX ( 38.7% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van DVAX ( 38.7% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van DVAX zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van DVAX ( 17.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van DVAX ( 17.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van DVAX naar verwachting over 3 jaar hoog zal zijn

Dynavax Technologies Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 23%, revenue downgraded

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Consensus EPS estimates fall by 39%

Consensus estimates of losses per share improve by 49%

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Recent updates

Dynavax Technologies Corporation to Report Q3, 2024 Results on Nov 07, 2024

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Dynavax Technologies: Slow And Steady Wins The Race

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Consensus EPS estimates increase by 23%, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dynavax Technologies Corporation to Report Q2, 2024 Results on Aug 06, 2024

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Dynavax Technologies Corporation Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Dynavax Technologies Corporation to Report Q1, 2024 Results on May 08, 2024

Dynavax Technologies Corporation, Annual General Meeting, May 23, 2024

Dynavax: Holding Firm Despite Its Missing Cash Cow

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS exceeds analyst expectations

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024

Dynavax Technologies Corporation to Report Q4, 2023 Results on Feb 22, 2024

CEO & Director exercised options and sold US$219k worth of stock

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Consensus EPS estimates fall by 39%

Insider notifies of intention to sell stock

President & COO notifies of intention to sell stock

Consensus estimates of losses per share improve by 49%

President & COO notifies of intention to sell stock

Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023

Dynavax Technologies Corporation to Report Q3, 2023 Results on Nov 02, 2023

President & COO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Dynavax Technologies Corporation to Report Q2, 2023 Results on Aug 03, 2023

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

President & COO recently sold US$191k worth of stock

Dynavax Technologies Corporation Reaffirms Revenue Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

CEO & Director exercised options and sold US$311k worth of stock

Consensus revenue estimates fall by 39%

Full year 2022 earnings: EPS exceeds analyst expectations

Dynavax Technologies Corporation to Report Q4, 2022 Results on Feb 23, 2023

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Price target decreased to US$22.75

President & COO recently sold US$651k worth of stock

President & COO recently sold US$651k worth of stock

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: US$0.50 (vs US$0.24 loss in 3Q 2021)

Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2022

Dynavax Technologies Corporation to Report Q3, 2022 Results on Nov 03, 2022

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Dynavax Technologies Corporation Announces First Participant Dosed in A Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 51%

Insider exercised options and sold US$178k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dynavax Technologies Corporation Revises Earnings Guidance for the Year 2022

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Now 21% undervalued

Dynavax Technologies Corporation to Report Q2, 2022 Results on Aug 04, 2022

Now 23% undervalued

Investor sentiment improved over the past week